Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore

References

• Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012;19(Suppl 1):10–17.
   PubMed Web of Science ®Google Scholar
• Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–479. doi: 10.1016/s0022-5347(17)49698-4.
   PubMed Web of Science ®Google Scholar
• Bortnick E, Brown C, Simma-Chiang V, et al. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol. 2020;12:1756287220929486. doi: 10.1177/1756287220929486.
   Web of Science ®Google Scholar
• Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-Initial work-up and medical management. J Urol. 2021;206(4):806–817. doi: 10.1097/JU.0000000000002183.
   PubMed Web of Science ®Google Scholar
• Yu ZJ, Yan HL, Xu FH, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol. 2020;11:658. doi: 10.3389/fphar.2020.00658.
   PubMed Web of Science ®Google Scholar
• Cindolo L, Pirozzi L, Sountoulides P, et al. Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol. 2015;15(1):96. doi: 10.1186/s12894-015-0090-x.
   PubMedGoogle Scholar
• Leong JY, Patel AS, Ramasamy R. Minimizing sexual dysfunction in BPH surgery. Curr Sex Health Rep. 2019;11(3):190–200. doi: 10.1007/s11930-019-00210-1.
   PubMedGoogle Scholar
• Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802–8813.
   PubMed Web of Science ®Google Scholar
• McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021;206(3):715–724. doi: 10.1097/JU.0000000000001778.
   PubMedGoogle Scholar
• Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. study. J Urol. 2013;190(6):2161–2167. doi: 10.1016/j.juro.2013.05.116.
   PubMed Web of Science ®Google Scholar
• McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–1538. doi: 10.1016/j.juro.2015.10.181.
   PubMed Web of Science ®Google Scholar
• Agency for Care Effectiveness. Medical technologies evaluation methods and process guide. Singapore: Ministry of Health Singapore; 2022.
   Google Scholar
• TreeAge Software. TreeAge pro 2021. Williamstown, MA: TreeAge Software; 2021. http://www.treeage.com.
   Google Scholar
• Loh AH, Ng KK, Ng FC. Presentation and progression of benign prostatic hyperplasia: a Singapore experience profiling ethnic differences in a multiracial study cohort. Ann Acad Med Singap. 2009;38(5):451–456. doi: 10.47102/annals-acadmedsg.V38N5p451.
   PubMed Web of Science ®Google Scholar
• Erman A, Masucci L, Krahn MD, et al. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis. BJU Int. 2018;122(5):879–888. doi: 10.1111/bju.14520.
   PubMed Web of Science ®Google Scholar
• Agency for Care Effectiveness. Drug evaluation methods and process guide. Singapore: ACE; 2019.
   Google Scholar
• Pearce F, Lin L, Teo E, et al. Health technology assessment and its use in drug policies: Singapore. Value Health Reg Issues. 2019;18:176–183. doi: 10.1016/j.vhri.2018.03.007.
   PubMedGoogle Scholar
• Don H, Michael D, Federico A, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10–31.
   PubMed Web of Science ®Google Scholar
• Health Promotion Board. Lower urinary tract symptoms suggestive of enlarged prostate gland. Singapore: Ministry of Health Singapore; 2006.
   Google Scholar
• Ng M, Baradhi KM. Benign prostatic hyperplasia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
   Google Scholar
• Chughtai B, Rojanasarot S, Neeser K, et al. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. PLOS One. 2022;17(4):e0266824. doi: 10.1371/journal.pone.0266824.
   PubMed Web of Science ®Google Scholar
• Ackerman SJ, Rein AL, Blute M, et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Urology. 2000;56(6):972–980. doi: 10.1016/s0090-4295(00)00828-1.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Tarricone R. Healthcare resource consumption for intermittent urinary catheterisation: cost-effectiveness of hydrophilic catheters and budget impact analyses. BMJ Open. 2017;7(1):e012360. doi: 10.1136/bmjopen-2016-012360.
   PubMed Web of Science ®Google Scholar
• Teo JS, Lee YM, Ho HSS. An update on transurethral surgery for benign prostatic obstruction. Asian J Urol. 2017;4(3):195–198. doi: 10.1016/j.ajur.2017.06.006.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131. doi: 10.1016/j.eururo.2009.09.035.
   PubMed Web of Science ®Google Scholar
• Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2018;10:29–43. doi: 10.2147/CEOR.S148195.
   PubMed Web of Science ®Google Scholar
• Sahakyan Y, Erman A, Bhojani N, et al. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study. Prostate Cancer Prostatic Dis. 2023;26(1):113–118. doi: 10.1038/s41391-022-00561-2.
   PubMed Web of Science ®Google Scholar